Abstract
This study is a combined modality Phase II therapeutic trial to determine the efficacy of the novel combination of VP-16, Vincristine and Procarbazine in addition to postoperative radiation therapy in patients with high grade intracranial gliomas. Thirty three patients (median age 51 years) were entered (27 with glioblastoma multiforme, 6 with anaplastic astrocytoma). Toxicity was manageable with no lethal toxicities. Five of seven life threatening toxicities were hematologic. Median overall survival was 14.2 months. These data suggest this regimen is effective treatment for patients with high grade gliomas.
Original language | English (US) |
---|---|
Pages (from-to) | 55-62 |
Number of pages | 8 |
Journal | Journal of neuro-oncology |
Volume | 37 |
Issue number | 1 |
DOIs | |
State | Published - Feb 25 1998 |
All Science Journal Classification (ASJC) codes
- Oncology
- Neurology
- Clinical Neurology
- Cancer Research